BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34608246)

  • 41. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
    Gerhard-Hartmann E; Rosenwald A
    Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma.
    Oliveira CC; Maciel-Guerra H; Kucko L; Hirama EJ; Brilhante AD; Quevedo FC; da Cunha IW; Soares FA; Niero-Melo L; Dos Reis PP; Domingues MA
    Diagn Pathol; 2017 Jan; 12(1):3. PubMed ID: 28061782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
    Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
    Yoon J; Yun JW; Jung CW; Ju HY; Koo HH; Kim SH; Kim HJ
    Genes Chromosomes Cancer; 2020 Apr; 59(4):255-260. PubMed ID: 31705772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
    Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
    Dheur MS; Poirel HA; Ameye G; Tilman G; Saussoy P; Defour JP; Camboni A; Van Den Neste E; Coulie PG; van Baren N
    Leuk Lymphoma; 2019 Apr; 60(4):1043-1052. PubMed ID: 30277098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.
    Kanagal-Shamanna R; Medeiros LJ; Lu G; Wang SA; Manning JT; Lin P; Penn GM; Young KH; You MJ; Vega F; Bassett R; Miranda RN
    Histopathology; 2012 Nov; 61(5):945-54. PubMed ID: 22804688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
    Li S; Qiu L; Xu J; Lin P; Ok CY; Tang G; McDonnell TJ; James You M; Khanlari M; Miranda RN; Medeiros LJ
    Leukemia; 2023 Feb; 37(2):422-432. PubMed ID: 36513804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.
    Johnson PC; Abramson JS
    Oncology (Williston Park); 2022 Aug; 36(8):499-505. PubMed ID: 36001789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flow cytometry is of limited utility in the early identification of "double-hit" B-cell lymphomas.
    Platt MY; DeLelys ME; Preffer FI; Sohani AR
    Cytometry B Clin Cytom; 2013 May; 84(3):143-8. PubMed ID: 23341189
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.
    Moore EM; Aggarwal N; Surti U; Swerdlow SH
    Am J Surg Pathol; 2017 Sep; 41(9):1155-1166. PubMed ID: 28614202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
    Grygalewicz B; Woroniecka R; Rymkiewicz G; Rygier J; Borkowska K; Kotyl A; Blachnio K; Bystydzienski Z; Nowakowska B; Pienkowska-Grela B
    Am J Clin Pathol; 2017 Dec; 149(1):17-28. PubMed ID: 29272887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical characteristics of high-grade B-cell lymphomas with rearrangement of MYC, bcl-6 and bcl-2].
    Gong JY; Zhang YZ; Zhang JD; Zhang W; Li JQ; Ru K; Liu EB
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):14-18. PubMed ID: 29325245
    [No Abstract]   [Full Text] [Related]  

  • 57. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
    Gebauer N; Bernard V; Feller AC; Merz H
    Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment strategy for high-grade B-cell lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2018; 59(10):2109-2116. PubMed ID: 30305516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.